MIRUM PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.04 USD | -0.30% |
|
+6.28% | +12.11% |
Presentation Operator MessageOperator (Operator)Welcome to the Mirum Business Update Call. My ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
33.14
USD
Average target price
56.36
USD
Spread / Average Target
+70.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.11% | 1.56B | |
| +27.04% | 52.73B | |
| +37.49% | 39B | |
| -9.36% | 38.52B | |
| +28.58% | 30.38B | |
| -12.26% | 26.39B | |
| +11.76% | 26.08B | |
| +45.18% | 14.15B | |
| +32.85% | 12.6B | |
| -5.46% | 11.51B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. - Special Call
